

Canterbury Medical Research Foundation

Consolidated Financial Statements

For the Year Ended 31 December 2024

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2024**


Contents	Page
Approval of Annual Report	1
Directory	2
Statement of Service Performance	3
Financial Statements	
Statement of Comprehensive Revenue and Expenses	12
Statement of Financial Position	13
Statement of Changes in Net Assets/Equity	14
Statement of Cash Flows	15
Notes to the Financial Statements	16-22
Independent Auditor's Report	

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**APPROVAL OF FINANCIAL REPORT
For the Year Ended 31 December 2024**


The Chairman and Treasurer are pleased to present the approved financial report including the historical financial statements of Canterbury Medical Research Foundation for year ended 31 December 2024.

APPROVED



Chairman of Canterbury Medical Research Foundation Incorporated
(on behalf of the Board)

Date 21 May 2025



Treasurer of Canterbury Medical Research Foundation Incorporated
(on behalf of the Board)

Date 21 May 2025

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

DIRECTORY

For the Year Ended 31 December 2024

Nature of Business	Provide grants and funding for medical and health research projects
Location of Business	66 Stewart Street Christchurch 8011
IRD Number	069-442-005
Accountants	BDO Christchurch Level 4, 287/293 Durham Street North Christchurch 8013
Auditors	BDO Christchurch Audit Limited Level 4, 287/293 Durham Street North Christchurch 8013
Bankers	ANZ
Registration Date	3/07/2007
Registration Number	858218
Executive Committee	Geoff Cranko Simon Carey Jessica Riddell Prof Ekant Veer Sue Sullivan (appointed 20 November 2024) Ross Hutton (Co-opted) Prof David Murdoch (Co-opted) Prof Sarah Young (Co-opted) - resigned 20 November 2024 Julie Patterson - resigned 20 November 2024 Prof Cameron Lacey - resigned 20 November 2024 Prof Gail Gillon - resigned 20 November 2024

Chair
Treasurer



Statement of Service Performance 2024

CMRF MISSION:	Investing in Canterbury's emerging health researchers and future leaders to achieve the best possible health and well-being outcomes for our communities
ASPIRATION:	The Canterbury Medical Research Foundation will be the leading charitable funder of emerging health and well-being researchers in Canterbury
VALUES:	Intellectual Rigour Community Connectedness Independent Enabler Legacy with Integrity

We bring the CMRF mission to life by following the below key performance measures that align with our CMRF strategic plan.

PERFORMANCE MEASURES PER CMRF STRATEGIC PLAN

1. Support excellence in health and well-being research by funding early to mid-career stage researchers in Canterbury
2. Develop research funding that supports the health and well-being aspirations of mana whenua
3. Raise awareness of the importance of investment in health and well-being research for positive outcomes for our communities
4. Expand our connections and collaborations with research institutions, health NGOs, funders, trusts and corporate partners
5. Develop a more diversified investor base to strengthen capital position and increase annual research funding

Significant Judgements

In compiling the CMRF Statement of Service Performance (SSP), the board and management have formulated judgements in relation to which outcomes and outputs best reflect the achievement of its performance based on the CMRF mission statement and strategic goals. Outputs and outcomes are derived from information recorded within the CMRF membership and grants portal, digital repositories and other information systems maintained by the CMRF.

The selection of the performance measures has been determined to be a significant judgement given the various of ways in which CMRF operate to achieve its mission.

The selection of Support excellence in health and well-being research by funding early to mid-career stage researchers in Canterbury, Raise awareness of the importance of investment in health and well-being research for positive outcomes for our communities and Develop a more diversified investor base to strengthen capital position and increase annual research funding has been determined as the most appropriate measures for reporting our impact on CMRF to invest in Canterbury's emerging health researchers and future leaders to achieve the best possible health and well-being outcomes for our communities.

The level of aggregation presented in the Statement of Service Performance is considered a significant judgement as the presentation of the measures has an impact on the users ability to understand and interpret CMRF reported performance, and assess how we are achieving our mission. The level of aggregation presented is determined to be the most appropriate level of detail to allow for useful interpretation of the measures reported.

There were no other significant judgements made in relation to the reported performance measures.

1. Support excellence in health and well-being research by funding early to mid-career stage researchers in Canterbury

Outcome 1:

Award funding of at least \$1m through various Grants and Fellowships

Performance measures:

Grant & Fellowship funding	2024	2023
Don Beaven Travel Grants	-	\$3,926
Emerging Researcher Fellowship	\$375,591	\$199,943
Grant in Aid	\$20,000	\$15,000
Major Project Grants	\$716,018	\$651,597
Special Projects and Joint Funding	\$190,030	\$98,760
Summer Studentships	\$130,000	\$84,000
UC Bursary/Scholarship	\$40,000	-
Travel Grants	\$4,809	\$3,725
Total Funded	\$1,476,448	\$1,056,951

Don Beaven Travel Grants – value up to \$5,000 total annually

- 2024
 - 0 applications received
 - 0 awarded
- 2023
 - 2 applications received
 - 2 awarded

Emerging Researcher Fellowship – value up to \$220,000 over two years

- 2024
 - 14 applications received
 - 6 applicants interviewed
 - 2 awarded
- 2023
 - 2 applications received
 - 2 applicants interviewed
 - 1 awarded

Grant in Aid – value up to \$5,000 each

- 2024
 - 7 applications received
 - 4 awarded
- 2023
 - 5 applications received
 - 3 awarded

Major Project Grants – value up to \$120,000 over two years

- 2024
 - Expressions of Interest - 23 applications received
 - Full applications – 15 invited
 - 6 awarded
- 2023
 - Expressions of Interest - 16 applications received
 - Full applications – 15 invited
 - 6 awarded

Special Projects and Joint Funding

- 2024
 - Haematology Grant \$90,030 funded by a bequest from the Fairlie Horsley Estate
 - Te Whatu Ora/Health NZ Emerging Researcher Grants in partnership with CMRF 5x awarded (\$20,000 each) \$100,000 funded by Te Whatu Ora/Health NZ
- 2023
 - Te Whatu Ora/Health NZ Emerging Researcher Grants in partnership with CMRF 5x awarded (\$20,000 each) \$100,000 funded by Te Whatu Ora/Health NZ

Summer Studentships/Scholarships –in partnership with University of Otago Christchurch (UOC) and University of Canterbury (UC)

- 2024
 - UOC \$120,000 to sponsor 20x (\$6,000 each) Future Health Researchers funded by Roland Stead Charitable Trust
 - UC \$10,000 to sponsor 4x Summer Studentships co-funded with UC
 - UC \$40,000 to sponsor a CMRF PhD Scholarship (3-year commitment of \$40k per year)
- 2023
 - UOC \$84,000 to sponsor 14x (\$6,000 each) Future Health Researchers funded by Roland Stead Charitable Trust

Travel Grants – value up to \$2,000 each

- 2024
 - 7 applications received
 - 3 awarded
- 2023
 - 4 applications received
 - 3 awarded

Outcome 2:

Sponsor and co-host events that support and acknowledge excellence and achievement of emerging researchers

Performance measures 2024:

- Hosted AGM featuring CMRF 2023 Emerging Researcher Fellow Dr Kyla-Louise Horne
- Sponsored and co-hosted the 'Let's Talk Research' public event with Te Papa Hauora featuring emerging and established Canterbury based researchers
- Sponsored and co-hosted the Health Research Society of Canterbury (HRSC) Poster Evening for emerging researchers and sponsored/presented the prizes
- Co-hosted the Health Research Society of Canterbury (HRSC) Emerging Researcher Talks event and sponsored/presented the prizes
- Co-hosted the "Living Well & Ageing Well" regional community talks in Rangiora (Waimakariri/North Canterbury) with Te Papa Hauora featuring emerging and established Canterbury based researchers
- Hosted the Professionals Lunch, sponsored by Craigs Investment Partners, featuring CMRF 2024 Emerging Researcher Fellow Dr Megan Gath
- Hosted the Christmas & Funding announcement function to celebrate and acknowledge the 2024 CMRF funded emerging researchers with brief presentations by all recipients

2023 comparison:

- Hosted AGM featuring CMRF Wine & Art Award recipient Prof Gail Gillon
- Sponsored and co-hosted the Health Research Society of Canterbury (HRSC) Poster Evening for emerging researchers
- Sponsored and co-hosted the Health Research Society of Canterbury (HRSC) Emerging Researcher Talks event
- Co-hosted the 'Let's Talk Research' and 'We're Talking Research' public events with Te Papa Hauora featuring emerging and established Canterbury based researchers

- Co-hosted the "Living Well & Ageing Well" regional community talks in Rangiora (Waimakariri/North Canterbury) with Te Papa Hauora featuring emerging and established Canterbury based researchers
- Co-hosted the "Living Well & Ageing Well" regional community talks in Lincoln (Selwyn) with Te Papa Hauora featuring emerging and established Canterbury based researchers
- Supported the University of Otago Christchurch Centre for Free Radical Research Symposium featuring emerging researchers
- Hosted the Major Project Grant announcement function to celebrate and acknowledge the 2023 CMRF funded emerging researchers
- Hosted the CMRF Xmas function which acknowledged the excellence and achievement of all the 2023 CMRF funded emerging researchers

**Outcome 3:
Fund projects across a range of research areas**

Performance measures:

Research Area	2024	2024	2023	2023
Brain Disease	\$45,000	3%	\$309,943	29%
Cancer	\$5,000	<1%	\$110,000	10%
Child Health	\$495,428	34%	\$119,992	11%
Heart	\$116,289	8%	\$109,843	10%
Immunology	\$125,000	8%		
Infectious Diseases	\$120,000	8%		
Mental Health			\$216,762	20%
Non-Infectious Diseases	\$119,983	8%		
Public Health	\$124,909	8%		
	\$1,151,609	78%	\$866,540	82%
Other Funding*	\$324,839	22%	\$190,411	18%
Total Funded	\$1,476,448	100%	\$1,056,951	100%

*Other Funding – Special Projects & Joint Funding, Summer Students, Travel Grants

2. Raise awareness of the importance of investment in health and well-being research for positive outcomes for our communities

**Outcome 1:
Host community events that showcase CMRF funded researchers to raise awareness of the quality of work undertaken locally**

Performance measures 2024:

- Hosted AGM featuring CMRF 2023 Emerging Researcher Fellow Dr Kyla-Louise Horne
- Co-hosted the "Living Well & Ageing Well" regional community talks in Rangiora (Waimakariri/North Canterbury) with Te Papa Hauora featuring emerging and established Canterbury based researchers with a sold out 100 attendees
- Co-hosted the 'Let's Talk Research' and 'We're Talking Research' public events with Te Papa Hauora featuring emerging and established Canterbury based researchers with over 200 people attendees (including in person and online)

2023 comparison:

- Hosted AGM featuring CMRF Wine & Art Award recipient Prof Gail Gillon

- Co-hosted the "Living Well & Ageing Well" regional community talks in Rangiora (Waimakariri/North Canterbury) and Lincoln (Selwyn) with Te Papa Hauora featuring emerging and established Canterbury based researchers with a sold out 100 attendees at each event
- Co-hosted the 'Let's Talk Research' and 'We're Talking Research' public events with Te Papa Hauora featuring emerging and established Canterbury based researchers with over 200 attendees at each event

Outcome 2:

Presentations to community groups and clubs alongside CMRF funded researchers to highlight the importance of investment into Canterbury based health research

Performance measures 2024:

- Guest speaker at the Zonta Canterbury Area Conference 2024
- North Canterbury community with Prof Richard Porter, Dr Leigh O'Brien & Dr Susanna Stevens
- Aged Concern with Prof Richard Porter, Dr Leigh O'Brien & Dr Susanna Stevens
- U3A clubs, Zonta and Rotary clubs with various researchers

2023 comparison:

- North Canterbury community with Assoc Prof Tracy Melzer, Prof Julia Rucklidge & Dr Kyla Horne (all previous or current CMRF funding recipients)
- Aged Concern with Assoc Prof Tracy Melzer, Prof Julia Rucklidge & Dr Kyla Horne (all previous or current CMRF funding recipients)
- Selwyn community with Dr Susannah Stevens and Prof Joe Boden (all previous or current CMRF funding recipients)
- U3A clubs, Zonta and Rotary clubs with various researchers

3. Develop a more diversified investor base to strengthen capital position and increase annual research funding

Outcome 1:

Attract and secure funding from trusts and organisations that wish to fund health research in Canterbury

Performance measures:

External funding received for grants	2024	2023
Major Project Grant funding	\$165,000	
Special Project funding	\$190,000	\$98,760
Summer Student funding	\$120,000	\$60,000
Total external funding received	\$475,000	\$158,760

External funding received for grants	2024	2023
Major Project Grant Funding	<ul style="list-style-type: none"> ○ Jeremy Lochhead Charitable Trust \$120,000 donation to co-fund two recipients ○ Neil & Pearl Hamilton Trust \$45,000 donation to co-fund one recipient 	○

Special Project Funding	<ul style="list-style-type: none"> ○ Te Whatu Ora Emerging Researcher Grants \$100,000 received to fund 5x \$20,000 grants ○ Estate of Fairlie Horsley funding Special Project Grant in haematology for \$90,000 	<ul style="list-style-type: none"> ○ Te Whatu Ora Emerging Researcher Grants \$100,000 received to fund 5x \$20,000 grants (1 grant was valued at \$18,760 not \$20,000)
Summer Student Funding	<ul style="list-style-type: none"> ○ Roland Stead Charitable Trust via Perpetual Trust contestable funding round for UOC Future Health Researchers Programme for \$120,000 (sponsoring 20 students over summer at \$6,000 each) 	<ul style="list-style-type: none"> ○ Roland Stead Charitable Trust via Perpetual Trust contestable funding round for UOC Future Health Researchers Programme for \$60,000 (sponsoring 10 students over summer at \$6,000 each)

**Outcome 2:
Develop a new bequest strategy**

Performance measures:

Bequests received	2024	2023
	\$1,982,995	\$1,518,845



**New Zealand
Brain Research
Institute**

Statement of Service Performance 2024

NZBRI MISSION: Improving brain-health through research, education and clinical practice

We do this by following the below key charitable aims to ensure the focus on improving brain-health through research, education and clinical practice

MAIN CHARITABLE AIMS:

1. To reveal new knowledge about the brain and its dysfunction
2. To improve the standard of care for people with neurological disorders, locally, nationally, and globally
3. To educate clinicians, scientists, and the public on brain research findings and techniques

1. Reveal new knowledge about the brain and its dysfunction

Outcome 1:

Submit funding applications to competitive funding rounds at external research funding bodies.

Performance measures:

Funding applications	2024	2023
Submitted	#33	#13
Decisions	26	**15
Successful	**10	8
Unsuccessful	*16	7
Total Value of Grants	\$ 1,171,510	\$1,897,176
Total Value to NZBRI	\$154,533	\$540,446

#Includes 16 EOIs and 17 full applications

**Includes 5 EOIs and 5 full applications that were successful

* Includes 7 EOIs and 9 full applications that were unsuccessful

Note: Successful number of full applications includes one application submitted in 2023

2. Improve the standard of care for people with neurological disorders

Outcome 1:

Operate the Christchurch branch of the national Dementia Prevention Research Clinic (DPRC).

The DPRC provides for intensive medical, neuropsychological, neuroimaging, and other assessments for patients at risk of progression to dementia. It provides a comprehensive clinical service for this group of patients that would not exist otherwise and is funded by the Dementia Prevention Research Trust.

Performance measures

DPRC	2024	2023
New Patients	7	12
Patients seen for their Year 2 follow-up	9	6
Patients seen for their Year 4 follow-up	9	11
Patients seen for their year 6 follow-up	12	2
Total Patients Assessed	37	31

Outcome 2:

Host clinical trials associated with neurological disorders

Performance measures

- 2024 - 178 visits across 8 active clinical trials covering Huntington's disease, Multiple System Atrophy, and Spinocerebellar Ataxia.
- 2023 – 240 visits across 6 active clinical trials covering the conditions of Huntington's disease, motor neuron disease, Multiple System Atrophy, and Parkinson's.

3. Educate clinicians, scientists, and the public on brain research findings and techniques

Outcome 1:

Provide opportunities to students to complete graduate qualification in brain research.

Performance measures

Graduate Qualifications	2024	2023
PhD	5	0
Masters	0	0

PhD qualifications supported in 2024 FY

Nicola Slater, School of Psychology, Speech, & Hearing, University of Canterbury
Title: *Parkinson's disease, cognition, and the cholinergic system*

Rebecca Lee, Dept. Medicine, University of Otago, Christchurch.
Title: *Early Cannabis Use and Its Impact on the Ageing Brain: an MRI Study of a New Zealand Longitudinal Birth Cohort*

Lee-Anne Morris, Dept. Medicine, University of Otago, Christchurch.
Title: *Cognitive and neural mechanisms underlying apathy in Huntington's disease and Parkinson's disease*

Eloise Gooch, School of Psychology, Speech, & Hearing, University of Canterbury
Title: *Behavioural and Neural Characteristics of Stuttered Disfluencies in Parkinson's disease*

Grace Hall-McMaster, Dept. Medicine, University of Otago, Christchurch
Title: *Parameterised resting state EEG, network integrity, structure and cognition in Parkinson's disease*

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**STATEMENT OF COMPREHENSIVE REVENUE AND EXPENSE
For the Year Ended 31 December 2024**

<i>Note</i>	Group 2024	Group 2023	Parent 2024	Parent 2023
REVENUE				
REVENUE FROM EXCHANGE TRANSACTIONS				
Subscriptions	342	511	342	511
Interest Received	362,772	295,120	327,990	271,469
Dividends Received	245,142	234,543	201,023	188,592
Event Income	94,159	100,649	-	-
Grant Income	321,259	160,000	321,259	160,000
Rent Received	156,083	108,078	-	-
Research Income	614,618	694,833	-	-
Management Fees	-	-	-	39,748
Sundry Income	-	10,040	-	9,440
Realised Gains/(Losses)	125,494	245,977	(1,020)	193,388
	<u>1,919,869</u>	<u>1,849,751</u>	<u>849,596</u>	<u>863,148</u>
REVENUE FROM NON-EXCHANGE TRANSACTIONS				
Bequests	2,158,505	1,109,254	1,982,995	1,107,401
Donations Received	257,810	580,088	227,876	571,959
	<u>2,416,315</u>	<u>1,689,342</u>	<u>2,210,872</u>	<u>1,679,359</u>
TOTAL REVENUE	<u>4,336,184</u>	<u>3,539,092</u>	<u>3,060,467</u>	<u>2,542,508</u>
EXPENSES				
Administration Expenses				
Accounting Fees	31,214	42,606	18,603	24,974
Audit Fees	22,800	18,830	13,100	9,550
Communication Costs	10,070	10,245	1,593	4,964
Depreciation Expense	34,416	39,932	3,277	2,963
Loss on Disposal of Fixed Assets	88	549	88	549
Loss on Disposal of Intangible Assets	-	26,060	-	-
Information Technology Support	26,968	44,194	9,300	11,086
Amortisation of Intangibles	2,298	4,597	2,298	4,597
KiwiSaver	19,322	21,529	-	899
Lease of Premises	235,289	268,829	49,730	36,674
Legal Expenses	-	500	-	500
Occupancy Costs	41,444	48,149	1,773	4,276
Marketing, Publicity and Functions	25,074	36,567	25,074	36,567
Portfolio Management Fees	37,363	32,498	31,796	27,284
Salaries - Administration	327,984	299,952	195,391	271,681
Other Expenses	142,951	134,415	37,083	38,601
Total Administration Expenses	<u>957,282</u>	<u>1,029,450</u>	<u>389,107</u>	<u>475,165</u>
Research Expenses				
Project Grants	1,306,448	863,801	1,306,448	863,801
Research Costs	71,519	86,001	-	-
Salaries - Research	668,196	694,253	-	-
Summer Studentship	170,000	84,000	170,000	84,000
Total Research Expenses	<u>2,216,163</u>	<u>1,728,055</u>	<u>1,476,448</u>	<u>947,801</u>
SURPLUS/(DEFICIT) FOR THE YEAR	<u>1,162,739</u>	<u>781,587</u>	<u>1,194,912</u>	<u>1,119,542</u>
Other Comprehensive Revenue and Expenses				
Net change in fair value of Investment financial assets	1,250,445	137,997	1,139,700	65,546
Total Other Comprehensive Revenue and Expenses	<u>1,250,445</u>	<u>137,997</u>	<u>1,139,700</u>	<u>65,546</u>
TOTAL COMPREHENSIVE REVENUE AND EXPENSES	<u>2,413,183</u>	<u>919,584</u>	<u>2,334,613</u>	<u>1,185,088</u>

This statement is to read in conjunction with the accompanying Notes and Independent Auditor's Report.

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024**

	<i>Note</i>	<i>Group 2024</i>	<i>Group 2023</i>	<i>Parent 2024</i>	<i>Parent 2023</i>
ASSETS					
Cash and Cash Equivalents	9	885,257	914,717	439,456	814,175
Receivables and Prepayments	9	203,946	274,274	126,910	77,617
Current Assets		<u>1,089,203</u>	<u>1,188,991</u>	<u>566,366</u>	<u>891,792</u>
Property, Plant & Equipment	5	273,573	238,898	2,863	6,228
Intangible Assets	6	2,298	4,597	2,298	4,597
Investments	9	18,454,315	15,704,789	16,104,598	13,357,612
Life Insurance Policies		88,375	86,609	88,375	86,609
Non Current Assets		<u>18,818,562</u>	<u>16,034,893</u>	<u>16,198,134</u>	<u>13,455,046</u>
Investments					
TOTAL ASSETS		<u>19,907,765</u>	<u>17,223,885</u>	<u>16,764,500</u>	<u>14,346,838</u>
LIABILITIES					
Payables	9	262,971	105,578	169,100	66,423
Unexpended Project Grants	9	1,884,805	1,920,241	1,884,805	1,920,241
Employee Benefits		63,869	55,034	25,872	15,556
Accrued Expenses		58,875	68,260	29,144	25,600
Income in Advance		655,525	502,525	5,658	-
Hire Purchase		-	3,709	-	3,709
Current Liabilities		<u>2,926,043</u>	<u>2,655,347</u>	<u>2,114,579</u>	<u>2,031,529</u>
TOTAL LIABILITIES		<u>2,926,043</u>	<u>2,655,347</u>	<u>2,114,579</u>	<u>2,031,529</u>
EQUITY					
Accumulated comprehensive revenue and expense		10,703,779	9,541,040	9,185,919	7,991,005
Revaluation Reserve		5,983,348	4,732,903	5,169,408	4,029,708
General Reserve Fund		294,595	294,595	294,595	294,595
Total Equity		<u>16,981,722</u>	<u>14,568,536</u>	<u>14,649,922</u>	<u>12,315,308</u>
NET ASSETS		<u>16,981,722</u>	<u>14,568,537</u>	<u>14,649,922</u>	<u>12,315,308</u>

This statement is to read in conjunction with the accompanying Notes and Independent Auditor's Report.

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**STATEMENT OF CHANGES IN EQUITY
For the Year Ended 31 December 2024**

	Note	Group				Parent			
		Accumulated Comprehensive Revenue and Expense	Revaluation Reserve	General Reserve Fund	Total Equity	Accumulated Comprehensive Revenue and Expense	Revaluation Reserve	General Reserve Fund	Total Equity
<i>Opening Equity as at 1 January 2023</i>		8,759,453	4,594,906	294,595	13,648,953	6,871,463	3,964,162	294,595	11,130,220
Changes in Equity for 2023									
Surplus/(Deficit) for the Year		781,587	-	-	781,587	1,119,542	-	-	1,119,542
Other Comprehensive Revenue and Expenses	10								
Net change in fair value of investment financial assets		-	137,997	-	137,997	-	65,546	-	65,546
Total Comprehensive Revenue and Expenses for the year		781,587	137,997	-	919,584	1,119,542	65,546	-	1,185,088
Balance at 31 December 2023		\$9,541,040	\$4,732,903	\$294,595	\$14,568,536	\$7,991,005	\$4,029,708	\$294,595	\$12,315,308
Changes in Equity for 2024									
Surplus/(Deficit) for the Year		1,162,739	-	-	1,162,739	1,194,912	-	-	1,194,912
Other Comprehensive Revenue and Expenses	10								
Net change in fair value of investment financial assets		-	1,250,445	-	1,250,445	-	1,139,700	-	1,139,700
Total Comprehensive Revenue and Expenses for the year		1,162,739	1,250,445	-	2,413,183	1,194,912	1,139,700	-	2,334,612
Closing Equity as at 31 December 2024		\$10,703,779	\$5,983,349	\$294,595	\$16,981,719	\$9,185,918	\$5,169,408	\$294,595	\$14,649,921

This statement is to read in conjunction with the accompanying Notes and Independent Auditor's Report.

CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS

STATEMENT OF CASH FLOWS
For the Year Ended 31 December 2024

Note	Group 2024	Group 2023	Parent 2024	Parent 2023
CASH FLOWS FROM OPERATING ACTIVITIES				
<i>Cash was provided from:</i>				
Donations and Bequests	2,414,549	1,692,997	2,209,105	1,683,014
Event Income	94,159	100,649	-	-
Grants	564,684	65,306	317,511	160,000
Members Subscriptions	342	511	342	511
Services Provided	614,619	810,440	-	39,748
Rent Received	156,083	108,078	-	-
Sundry Income	-	10,040	-	9,440
Net GST Proceeds	-	11,368	-	4,959
	3,844,436	2,799,389	2,526,958	1,897,672
<i>Cash was applied to:</i>				
Grants	-	-	-	-
Cash Paid to Suppliers and Employees	(3,020,842)	(2,425,510)	(1,740,625)	(1,140,061)
Net GST Paid	(41,084)	-	(41,889)	-
	(3,061,926)	(2,425,510)	(1,782,514)	(1,140,061)
Net Cash Inflow (Outflow) from Operating Activities	782,510	373,879	744,444	757,610
CASH FLOWS FROM INVESTING ACTIVITIES				
<i>Cash was received from:</i>				
Investment Income	628,365	18,205	24,546	13,538
Net Disposals/(Acquisitions) of Fund Investment	-	-	-	-
	628,365	18,205	24,546	13,538
<i>Cash was applied to:</i>				
Acquisition of Property, Plant and Equipment	(3,709)	(207)	(3,709)	(207)
Net Disposals/(Acquisitions) of Fund Investment	(1,436,626)	-	(1,140,000)	(100,000)
	(1,440,335)	(207)	(1,143,709)	(100,207)
Net Cash Inflow (Outflow) from Investing Activities	(811,970)	17,998	(1,119,163)	(86,669)
Net (decrease)/increase in cash and cash equivalents	(29,460)	391,877	(374,719)	670,941
Cash Balances in Statement of Financial Position				
Opening Bank Accounts and Cash	914,717	522,840	814,175	143,234
Closing Bank Accounts and Cash	885,257	914,717	439,456	814,175

This statement is to read in conjunction with the accompanying Notes and Independent Auditor's Report.

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 December 2024**

	Page
1 <i>REPORTING ENTITY</i>	17
2 <i>BASIS OF PREPARATION</i>	17
3 <i>USE OF ESTIMATES AND JUDGEMENTS</i>	17
4 <i>SIGNIFICANT ACCOUNTING POLICIES</i>	17
5 <i>PROPERTY, PLANT & EQUIPMENT</i>	20
6 <i>INTANGIBLE ASSETS</i>	20
7 <i>CONTINGENT LIABILITIES</i>	20
8 <i>CAPITAL COMMITMENTS</i>	21
9 <i>FINANCIAL INSTRUMENTS</i>	21
10 <i>RESERVES</i>	21
11 <i>OPERATING LEASE COMMITMENTS</i>	21
12 <i>RELATED PARTIES</i>	21
13 <i>RECONCILIATION OF NET CASH FLOWS</i>	22
14 <i>GROUP ENTITIES</i>	22
15 <i>BASIS OF CONSOLIDATION - ACCOUNTING POLICY</i>	22

This statement is to read in conjunction with the accompanying Notes and Independent Auditor's Report.

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 December 2024**

1 REPORTING ENTITY

Canterbury Medical Research Foundation Incorporated (the "Society") is a legal form of public benefit (not-for-profit) entity in accordance with the Financial Reporting Act 2013, domiciled in New Zealand and registered under the Charities Act 2005.

For the purposes of financial reporting, Canterbury Medical Research Foundation Incorporated is a public benefit entity (not-for-profit).

Financial statements for the society and consolidated financial statements are presented. The consolidated financial statements of Canterbury Medical Research Foundation Incorporated as at and for the year ended 31 December 2024 comprises the society and its controlled entity New Zealand Brain Research Limited, together referred to as the Group.

The society's main operation is to provide grants and funding for medical and health research projects.

2 Basis of Preparation

(a) Statement of compliance

The financial statements have been prepared in accordance with and comply with New Zealand Generally Accepted Accounting Practice ("NZ GAAP"). They comply with Tier 2 PBE Accounting Standards — Reduced Disclosure Regime (Not-For-Profit). The society qualifies to report under Tier 2 as it has no public accountability and for the two most recent reporting periods has had less than \$33 million operating expenditure. Although the society could adopt Tier 3 as its total expenses are less than or equal to \$5 million, it is opting up to Tier 2 for consistency.

The financial statements were authorised for issue by the Board on 21 May 2023.

(b) Basis of measurement

The financial statements have been prepared on the historical cost basis except for the following material items in the statement of financial position:

• Investments are measured at fair value

The financial statements are prepared on an accrual basis.

We have opted for Tier 2 PBE IPSAS 29, IPSAS 30 and IPSAS 41 financial instruments for financial instruments.

(c) Functional and presentation currency

The financial statements are presented in New Zealand dollars, which is the functional and reporting currency of the society and all values are rounded to the nearest dollar except where indicated otherwise.

(d) Impairment

The carrying amounts of the society's non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. Indefinite-lived intangible assets are tested annually for impairment.

An impairment loss is recognised if the carrying amount of an asset or its related cash-generating unit (CGU) exceeds its estimated recoverable amount. The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs.

Impairment losses are recognised in profit or loss. Impairment losses recognised in respect of CGUs are allocated first to reduce the carrying amount of any goodwill allocated to the CGU (group of CGUs), and then to reduce the carrying amounts of the other assets in the CGU (group of CGUs) on a pro rata basis.

An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

3 Use of Estimates and judgements

The preparation of the financial statements in conformity with PBE Standards requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Assumptions and estimation uncertainties

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ending 31 December 2024 is included in the following notes:

• Note 4(d) — assessment of useful lives and residual values

4 Significant Accounting Policies

The accounting policies set out below have been applied in preparing the financial statements for the year ended 31 December 2024. Revenue is recognised when the amount of revenue can be measured reliably and it is probable that economic benefits will flow to the Group, and measured at the fair value of consideration received or receivable. The following specific recognition criteria in relation to the Group's revenue streams must also be met before revenue is recognised.

(a) Revenue from exchange transactions

Rental income from sub-lease

Rental income arising from sub-leasing the offices is accounted for on a straight-line basis over the lease term and included in revenue. The aggregate cost of lease incentives provided is recognised as a reduction of rental revenue over the lease term on a straight-line basis.

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 December 2024**

Interest income

Interest income is earned for the use of cash and cash equivalents or any amounts due to the society.

Interest income is recognised in the statement of comprehensive revenue and expense as it is earned. Interest income is accrued using the effective interest rate method. The effective interest rate exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount. The method applies this rate to the principal outstanding to determine interest revenue each period.

Dividend income

Dividend income is recognised in the statement of comprehensive revenue and expense as it is earned.

Services

Revenue from services rendered is recognised in the statement of comprehensive revenue and expense when the service is provided.

(b) Revenue from non-exchange transactions

Non-exchange transactions are those where the society receives value from another entity (e.g. cash or other assets) without giving approximately equal value in exchange.

Inflows of resources from non-exchange transactions, other than services in-kind, that meet the definition of an asset are recognised as an asset only when:

- It is probable that the society will receive an inflow of economic benefits or service potential; and
- The fair value of can be measured reliably.

Inflows of resources from non-exchange transactions that are recognised as assets are recognised as non-exchange revenue, to the extent that a liability is not recognised in respect to the same inflow.

Liabilities are recognised in relation to inflows of resources from non-exchange transactions when there is a resulting present obligation as a result of the non-exchange transactions, where both:

- It is probable that an outflow of resources embodying future economic benefit or service potential will be required to settle the obligation, and
- The amount of the obligation can be estimated reliably.

The following are the specific recognition criteria in relation to the society's non-exchange transactions.

Grants, Donations, Legacies and Bequests

Gifts, Donations and Bequests are voluntary transfers of assets including cash or other monetary assets, goods in-kind and services in-kind that the society receives which are free from stipulations.

Gifts, Donations and Bequests are recognised as revenue when it is probable that the future economic benefits or service potential will flow to the entity, and the fair value of the assets can be measured reliably. For gifts and donations this is usually upon receipt of the gift or donation. However for bequests, a period of time may elapse between the death of the testator and the entity receiving any assets — in which case the entity makes an assessment of whether the deceased person's estate is sufficient to meet all claims on it and satisfy all bequests. If the will is disputed, this is taken into account in determining the probability of assets flowing to the entity. Gifts, donations and bequests are recognised as revenue at their fair value at the date of recognition.

The recognition of non-exchange revenue from Grants, Donations, Legacies and Bequests depends on the nature of any stipulations attached to the inflow of resources received, and whether this creates a liability (i.e. present obligation) rather than the recognition of revenue.

Stipulations that are 'conditions' specifically require the Group to return the inflow of resources received if they are not utilised in the way stipulated, resulting in the recognition of a non-exchange liability that is subsequently recognised as non-exchange revenue as and when the 'conditions' are satisfied.

Stipulations that are 'restrictions' do not specifically require the Group to return the inflow of resources received if they are not utilised in the way stipulated, and therefore do not result in the recognition of a non-exchange liability, which results in the immediate recognition of non-exchange revenue.

(c) Taxes

The society is a registered charitable organisation and is therefore exempt from income tax.

(d) Property, plant and equipment

All property, plant and equipment are stated at cost less accumulated depreciation and impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the items.

Where an asset is acquired in a non-exchange transaction for nil or nominal consideration the asset is initially measured at its fair value.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the society. All other repair and maintenance costs are recognised in surplus or deficit as incurred.

Depreciation is calculated to write off the cost of items of property, plant and equipment less their residual values using the diminishing value method over their useful lives, and is recognised in surplus or deficit. The depreciation rates used are as follows:

Leasehold improvements -	12.0% - 48.0% diminishing value
Research equipment and furniture -	11.4% - 67.0% diminishing value
Software -	50.0% diminishing value

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

The assets' residual values and useful lives are reviewed, and adjusted prospectively, if appropriate, at the end of each reporting period.

(e) Leases

Canterbury Medical Research Foundation Incorporated and New Zealand Brain Research Limited holds the lease for the office and subleases this out to other entities.

Rent received from an operating lease is recognised as income on a straight-line basis over the lease term, net of the cost of any incentives granted to the lessee in negotiating the lease.

Initial direct costs incurred in negotiating an operating lease are added to the carrying amount of the leased asset and recognised over the lease term.

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 December 2024**

(f) Financial instruments

Financial assets

Initial recognition and measurement

Financial assets within the scope of PBE IPSAS 41 Financial Instruments: Recognition and Measurement are classified as financial assets at fair value through surplus or deficit, fair value through other comprehensive revenue and expense, or amortised cost, as appropriate.

The society determines the classification of its financial assets at initial recognition. The society initially recognises loans and receivables on the date that they are originated. All other financial assets (including assets designated at fair value through other comprehensive revenue and expense) are recognised initially on the settlement date at which the asset is delivered to the society.

All financial assets are recognised initially at fair value plus directly attributable transaction costs, except for financial assets at fair value through other comprehensive revenue and expense which do not include transaction costs.

The society's financial assets include: cash and short-term deposits; trade and other receivables and fund investments. Trade and other receivables are classified as loans and receivables. Fund investments are classified as financial assets at fair value through other comprehensive revenue and expense (designated on initial recognition).

Derecognition and offsetting

Group derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Group is recognised as a separate asset or liability. The Group derecognises a financial liability when its contractual obligations are discharged, cancelled, or expire. The Group also derecognises financial assets and financial liabilities when there has been significant changes to the terms and/or the amount of contractual payments to be received/paid. Financial assets and liabilities are offset and the net amount presented in the Statement of Financial Position when, and only when, the Group has a legal right to offset the amounts and intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

Subsequent measurement

The subsequent measurement of financial assets depends on their classification.

Receivables

Receivables are stated at estimated realisable value after providing against debts where collection is doubtful. Bad debts are written off during the period in which they are identified.

Investments

Under PBE IPSAS 41, the investment portfolio is not held for trading, and is instead designated for long-term holding for capital growth. As such, the society classifies and measure investment portfolio at fair value through other comprehensive revenue and expense.

After initial measurement, financial investments are subsequently measured at fair value with gains or losses recognised in other comprehensive revenue and expense and accumulated in the fair value reserve until the financial asset is derecognised, at which time the cumulative gain or loss in equity is reclassified to surplus or deficit.

Fair value is measured by the market value provided by the fund manager.

Impairment of investment financial assets

For investment portfolio, the society assesses at each reporting date whether there is objective evidence that an investment or a group of investments is impaired. In the case of financial assets classified and measured as fair value through other comprehensive revenue and expense, objective evidence would include a significant or prolonged decline in the fair value of the investment below its cost. "Significant" is evaluated against the original cost of the investment and "prolonged" against the period in which the fair value was below its original cost. Where there is evidence of impairment, the cumulative loss - measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that investment previously recognised in the surplus or deficit - is removed from the reserve in equity and recognised in surplus or deficit.

(g) Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and cash at bank, deposits on call and highly liquid investments with an original maturity of three months or less, which are readily convertible to known amounts of cash and are subject to insignificant risk of changes in value.

Contingent liabilities

The society does not recognise a contingent liability, but discloses details of any contingencies in the notes to the financial statements, unless the possibility of an outflow of resources embodying economic benefits or service potential is remote.

Contingent assets

The society does not recognise a contingent asset, but discloses details of a possible asset whose existence is contingent on the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group in the notes to the financial statements. Contingent assets are assessed continually to ensure that developments are appropriately reflected in the financial statements. If it has become virtually certain that an inflow of economic benefits or service potential will arise and the asset's value can be measured reliably, the asset and the related revenue are recognised in the financial statements of the period in which the change occurs.

(h) Employee benefits

Short and long-term employee benefits.

Short-term employee benefit liabilities are recognised when the Group has a legal or constructive obligation to remunerate employees for services provided and that are expected to be settled wholly before 12 months after the reporting date. Short-term employee benefits are measured on an undiscounted basis and expensed in the period in which employment services are provided. Add: defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognised as an employee benefit expense in surplus or deficit in the periods during which services are rendered by employees.

Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognised as an employee benefit expense in surplus or deficit in the periods during which services are rendered by employees.

CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 December 2024

(i) Related parties

The society regards a related party as a person or an entity with the ability to exert control individually or jointly, or to exercise significant influence over the society, or vice versa. Members of key management are regarded as related parties and comprise the executive committee of the society.

5 Property, Plant and Equipment

GROUP

In New Zealand Dollars	Software	Leasehold Improvements	Research and Office Equipment and Furniture	Total
Cost				
Balance as at 1 January 2023	2,098	369,197	544,191	915,486
Additions	-	-	3,920	3,920
Balance as at 31 December 2023	2,098	369,197	548,110	919,405
Additions	-	-	69,178	69,178
Balance as at 31 December 2024	2,098	369,197	617,288	988,583
Depreciation and Impairment				
Balance as at 1 January 2023	1,954	157,872	480,196	640,022
Depreciation	72	31,147	8,712	39,931
Loss on Sale	-	-	553	553
Balance as at 31 December 2023	2,026	189,019	489,461	680,506
Depreciation	-	-	34,416	34,416
Loss on Sale	-	-	88	88
Balance as at 31 December 2024	2,026	189,019	523,965	715,010
Net Book Values				
Balance as at 31 December 2023	72	180,178	58,649	238,898
Balance as at 31 December 2024	72	180,178	93,323	273,573

PARENT

In New Zealand Dollars	Software	Leasehold Improvements	Research and Office Equipment and Furniture	Total
Cost				
Balance as at 1 January 2023	-	-	90,914	90,914
Additions	-	-	3,920	3,920
Balance as at 31 December 2023	-	-	94,834	94,834
Balance as at 31 December 2024	-	-	94,834	94,834
Depreciation and Amortisation				
Balance as at 1 January 2023	-	-	85,090	85,090
Depreciation	-	-	2,963	2,963
Loss on Sale	-	-	553	553
Impairment	-	-	-	-
Balance as at 31 December 2023	-	-	88,606	88,606
Depreciation	-	-	3,277	3,277
Loss on Sale	-	-	88	88
Balance as at 31 December 2024	-	-	91,971	91,971
Net Book Values				
Balance as at 31 December 2023	-	-	6,228	6,228
Balance as at 31 December 2024	-	-	2,863	2,863

6 Intangible Assets

In New Zealand Dollars	Group Website	Parent Website
Cost		
Balance as at 1 January 2023	110,117	84,057
Write-offs	(26,060)	-
Balance as at 31 December 2023	84,057	84,057
Balance as at 31 December 2024	84,057	84,057
Amortisation		
Balance as at 1 January 2023	74,863	74,863
Amortisation	4,597	4,597
Balance as at 31 December 2023	79,460	79,460
Amortisation	2,298	2,298
Balance as at 31 December 2024	81,758	81,758
Net Book Values		
Balance as at 31 December 2023	4,597	4,597
Balance as at 31 December 2024	2,298	2,298

7 Contingent Liabilities

There were no contingent liabilities at 31 December 2024. (2023: Nil)

CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 December 2024

8 Capital Commitments

There were no capital commitments liabilities at 31 December 2024. (2023: Nil)

9 Financial Instruments

(a) Categories of financial assets and liabilities

<i>In New Zealand Dollars</i>	Group 2024	Group 2023	Parent 2024	Parent 2023
Financial Assets				
Investments				
Craigs Investment Partners Portfolio - general fund investments	18,454,315	15,704,789	16,104,598	13,357,612
	18,454,315	15,704,789	16,104,598	13,357,612
Loans and Receivables				
Cash and Cash Equivalents	885,257	914,717	439,456	814,175
Receivables	203,946	274,274	126,910	77,617
	1,089,203	1,188,991	566,366	891,792
Total Financial Assets	19,543,518	16,893,780	16,670,964	14,249,404
Financial Liabilities				
Financial Liabilities Measured at Amortised Cost				
Payables	262,971	105,578	169,100	66,423
Unexpended Project Grants	1,884,805	1,920,241	1,884,805	1,920,241
Total Financial Liabilities	2,147,775	2,025,819	2,053,904	1,986,665

Amortised Cost Financial Liabilities

Financial liabilities classified as amortised cost are non-derivative financial liabilities that are not classified as fair value through surplus or deficit financial liabilities. Financial liabilities classified as amortised cost are subsequently measured at amortised cost using the effective interest method. Financial liabilities classified as amortised cost comprise cash and cash equivalents (bank overdrafts), payables, loans, finance lease payable etc.

(b) Fair values

The fair value of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.

The portfolio investments are stated at market value per the fund manager.

10 Reserves

Revaluation Reserve

The fair value reserve comprise the cumulative net change in the fair value of investment financial assets. This is made up of unrealised/realised gains on investment portfolios.

General Reserve Fund

The general reserve fund comprises the net change in fair value of all other reserves.

11 Operating Lease Commitments

	Group 2024	Group 2023	Parent 2024	Parent 2023
Non-cancellable operating lease commitments				
Current Portion	165,872	159,497	50,000	15,204
Non-Current Portion - 1-5 years	110,581		33,333	-
Total operating lease commitments	276,453	159,497	83,333	15,204

Canterbury Medical Research Foundation Incorporated leases 16-18 St Asaph Street and New Zealand Brain Research Limited leases 66 Stewart Street from Stewart Street Holdings Limited. These leases were renewed for a term of 2 years to expire on 14 September 2026.

12 Related Parties

Key management personnel

Melissa Haberfield was appointed Foundation Director in March 2021. The total remuneration of the senior management group and the number of managers, on a full-time equivalent basis, receiving remuneration in this category are:

	2024	2023
Total Remuneration	170,000	159,077
Number of Persons	1	1

Other transactions

The Canterbury Medical Research Foundation Incorporated also has transactions with entities associated with Ross Hutton, who was a member of the executive committees.

	2024	2023
- Craigs Investment Partners - Ross Hutton	37,363	32,498

**CANTERBURY MEDICAL RESEARCH FOUNDATION
CONSOLIDATED FINANCIAL STATEMENTS**

**NOTES TO THE FINANCIAL STATEMENTS
For the Year Ended 31 December 2024**

13 Reconciliation of net cash flows from operating activities to surplus/(deficit)

<i>In New Zealand Dollars</i>	Group 2024	Group 2023	Parent 2024	Parent 2023
<i>Surplus/(deficit) for the year</i>	1,162,739	781,587	1,194,912	1,119,542
Non-cash movements				
Depreciation	34,416	39,932	3,277	2,963
Amortisation	2,298	4,597	2,298	4,597
Loss on disposal of fixed assets	88	549	88	549
Loss on disposal of intangible assets	-	26,060	-	-
Changes in fair value of Investment financial assets	(1,250,445)	(849,115)	(1,139,700)	(665,717)
Add/(deficit) movements in working capital				
Increase/(decrease) in payables	306,683	108,074	104,626	31,193
Increase/(decrease) in accrued expenses	(551)	27,617	13,860	12,459
Increase/(decrease) in project grants	(35,436)	209,445	(35,436)	209,445
Increase/(decrease) in receivables	(125,707)	(83,326)	3,748	3,027
Increase/(decrease) in other current assets	55,379	2,486	45,545	
Less Items classified as investing				
Investment Income	(628,365)	(18,205)	(24,546)	(13,538)
(Gain)/loss in investment proceeds	1,261,411	341,055	575,772	234,558
Net Cash flows from operating activities	782,510	590,756	744,444	939,078

14 Group Entities

	Country of Incorporation	<i>Ownership Interest</i>	
		2024	2023
		%	%
New Zealand Brain Research Institute Limited	New Zealand	100	100
Canterbury Medical Research Foundation	New Zealand	100	100

All controlled entities have the same reporting date as the controlling entity. There are no significant restrictions regarding to the transfer of dividends, loan repayments, and other funds from controlled entities.

15 Basis of consolidation – accounting policy

i. Controlled entities

Controlled entities are entities controlled by the Group. The Group controls an investee if all three of the following elements are present: power over the investee, exposure to variable returns from the investee, and the ability of the investor to use its power to affect those variable returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control. The financial statements of the Group's controlled entities are included in the consolidated financial statements from the date that control commences until the date that control ceases.

Subsequent changes in a controlled entity that do not result in a loss of control are accounted for as transactions with owners of the controlling entity in their capacity as owners, within net assets/equity.

The financial statements of the controlled entities are prepared for the same reporting period as the controlling entity, using consistent accounting policies.

ii. Loss of control of a controlled entity

On the loss of control, the Group derecognises the assets and liabilities of the controlled entity, any non-controlling interest, and the other components of net assets/equity related to the controlled entity. Any surplus or deficit arising on the loss of control is recognised in surplus or deficit.

If the Group retains any interest in the previously controlled entity, then such interest is measured at fair value at the date that control is lost. Subsequently, the retained interest is either accounted for as an equity-accounted associate or an investment financial asset depending on the level of influence retained.

iii. Non-controlling interests

Non-controlling interests are measured either, on a PBE combination acquisition by acquisition basis, their proportionate share of the acquiree's identifiable net assets, or fair value.

Non-controlling interests are allocated their share of net surplus or deficit after tax in the consolidated statement of comprehensive revenue and expense and are presented within equity in the consolidated statement of financial position separately from equity attributable to owners of the controlling entity.

iv. Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealised income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements.

Unrealised gains arising from transactions with equity accounted associates and jointly-controlled-entities are eliminated against the investment to the extent of the Group's interest in the investee.

Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment.

v. Loss of significant influence or joint control

Upon loss of significant influence of an associate, or joint control over the joint venture, the Group measures and recognises any remaining investment at its fair value, and accounts for the remaining investment at fair value in accordance with PBE IPSAS 29. Any difference between the carrying amount of the associate or joint venture upon loss of significant influence or joint control and the fair value of the retained investment and proceeds from disposal is recognised in surplus or deficit.